

Authera Enters into a Collaborative Agreement with The Jackson Laboratory to Combine Expertise on FcRn Biology in a Translational Perspective

May 25 - 2023, Oslo - Norway

Authera AS and The Jackson Laboratory (JAX), an independent, non-profit biomedical research organization, have announced an agreement to combine their expertise in the dynamics of pharmacokinetic regulation involving interactions between the neonatal Fc receptor (FcRn) and its ligands, IgG antibodies and albumin.

The agreement will leverage Authera AS' sophisticated technology platform, which can inform and fine-tune molecular designs targeting FcRn that translate into distinct pharmacokinetic parameters in state-of-the-art mice, and JAX's FcRn humanized mouse models allowing for the assessment of pharmacokinetics in vivo and further driving therapeutic development through the pipeline. JAX FcRn humanized mice allow researchers to investigate the effects of molecular engineering on the stability of their drug candidates and to predict their serum half-life in patients.

The parties' in vitro and in vivo technology advancements help address the binding differences between the receptor and its ligands *across species* that should be taken into consideration during preclinical development programs involving any modality with the capacity to interact with FcRn. The services provided by JAX and Authera improve the transition from in vitro to in vivo efficacy testing for drug developers.

Co-founder and chairman of Authera, Jan Terje Andersen, has, for more than a decade, collaborated with JAX on the use of their engineered mouse models in a translational perspective, where protocols have been developed to secure optimal conditions during evaluation of engineered IgG- and albumin-based designs.

“Authera is excited to join forces with JAX to explore common ground and to utilize their portfolio of mouse models tailored for human FcRn biology. This is highly important to secure optimal conditions during preclinical development of therapeutic candidates since most conventional mouse models are suboptimal for testing of FcRn-targeted molecules” – CEO, Simone Mester.

On June 14, Simone Mester will take part in a JAX-organized symposium in Zürich entitled “Translational Humanized Models for Antibody Drug Development.” This seminar will focus on the role of genetically and immune system-humanized models in the antibody drug development pipeline. Antibody developers will hear how leaders in the field use humanized models to predict and optimize the clinical performance of their drug candidate.

“At JAX, we are focused on delivering innovative tools to the global scientific community in support of advancing preclinical drug discovery. Our new relationship with Authera aligns precisely with our goals, providing translationally relevant models and data to make the appropriate dose selection for first in human clinical trials,” said David Grass, vice president operations, JAX Mice(R) and Clinical Research Services.



The Life Sciences Practice Group at Schjødt acts as legal counsel for Authera AS, and includes Tord Fondevik, Knut Sverre Skurdal Andresen and Jenny Nondal.

About Authera

Authera AS is a pre-clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic biologics. The company's knowledge is based on the understanding of crucial biological processes involving FcRn combined with a high-end and sophisticated technology platform. This platform can educate and fine-tune molecular designs to secure their optimal FcRn mediated cellular transport behavior, which translates into favorable in vivo pharmacokinetic parameters in state-of-the-art mouse models. Authera is a spinout from the Laboratory of Adaptive Immunity and Homeostasis at University of Oslo and Oslo University Hospital, headed by Professor Jan Terje Andersen. Co-founders are Professor emerita Inger Sandlie, CEO Simone Mester and CSO Torleif Tollefsrud Gjølberg. For more information, visit www.authera.bio and follow us in LinkedIn and Twitter.

About The Jackson Laboratory

The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations across the United States (Maine, Connecticut, California), Japan and China. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org.